AbbVie is about to release earnings. Ponder the Bull Case Scenario:
Humira represents one of the top immunology drugs for RA, Crohn’s disease, and psoriasis. It is expected to continue penetrating their respective markets.
Competitive RA threat from Pfizer’s Xeljanz will not likely take much share from Humira initially as Xeljanz’s safety and efficacy profile is still uncertain and the drug requires heavy monitoring during usage.
AbbVie has reached agreement Shire on the final terms of its takeover offer. This represents approximately $269 per Shire ADR.
Inversion tax strategy could cover a lot of bills when it works.
George Gutowski writes from a caveat emptor perspective.